What are the risks associated with Trecondi?
One year after the transplant, 96% of the children given Trecondi and 88% of those given busulfan were alive. In an additional study involving 101 children with other severe disorders requiring a bone marrow transplant, none of the 51 children given Trecondi had died from causes related to transplantation in the 3 months after the procedure, compared with 5 out of 50 children given busulfan (with fludarabine). In another study involving 70 children with blood cancers, 99% of the children given Trecondi (with fludarabine) were alive 3 months after their transplant 91% of the children were alive after one year and 84% after three years. In one of the studies, involving 570 adults with acute myeloid leukaemia (a blood cancer) or myelodysplastic syndromes (conditions in which large numbers of abnormal blood cells are produced), 64% of patients given Trecondi (with fludarabine) had a successful transplant and were alive and disease-free after 2 years, compared with 51% of patients given busulfan (with fludarabine). Three main studies showed that Trecondi is at least as effective as busulfan, another medicine used to prepare patients for haematopoietic stem cell transplantation.
0 kommentar(er)
